Please login to the form below

Not currently logged in
Email:
Password:

Kevzara

This page shows the latest Kevzara news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s Dupixent and Praluent fall short

Regeneron’s Dupixent and Praluent fall short

And another new launch - Kevzara (sarilumab) for rheumatoid arthritis - also missed expectations and made just $12m.

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics